MetaVia's DA-1726 demonstrated a statistically significant 1.47 mg/dL placebo-adjusted reduction in uric acid, strengthening the drug's metabolic profile ahead of planned 2027 Phase 2 trials for liver-related diseases.
The company reported a statistically significant 1.47 mg/dL placebo-adjusted uric acid reduction (p<0.001) after 16 weeks of DA-1726, adding to the previously reported 68.1% liver fat and 13.5% weight-loss reductions. Positive clinical signals strengthen the drug's metabolic profile ahead of a Phase 2 in MetALD/ALD planned for H2 2027. The very small sample (15 drug vs 4 placebo subjects) and the fact these data were already largely reported limit the surprise.
MetaVia Inc. announced additional Phase 1 Part 3B data for its DA-1726 drug candidate, showing a 1.47 mg/dL placebo-adjusted reduction in uric acid levels after 16 weeks. These findings build on previously reported clinical results, including a 68.1% reduction in liver fat and 13.5% weight loss, as the company prepares for a Phase 2 study in MetALD and ALD scheduled for the second half of 2027.
Additional data from the Phase 1 Part 3B trial showing DA-1726 reduced uric acid by 1.47 mg/dL versus placebo (p<0.001) after 16 weeks, on top of previously reported 68.1% liver fat reduction and 13.5% placebo-adjusted weight loss.
Full Part 3A and Part 3B data are expected in the first quarter of 2027, and a 48-week Phase 2 study in up to 150 subjects with MetALD and ALD is targeted to begin in the second half of 2027.